Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 15/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.51 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914009 | 0.90 | SYK (0.61) | SYKEGFRMAPK8MAPK9MAP4K3 | |
| SCHEMBL914191 | 0.90 | SYK (0.61) | SYKEGFRMAPK8MAPK9MAP4K3 | |
| SCHEMBL914008 | 0.90 | SYK (0.61) | SYKEGFRMAPK8MAPK9MAP4K3 | |
| SCHEMBL13074406 | 0.90 | SYK (0.61) | SYKEGFRMAPK8MAPK9MAP4K3 | |
| SCHEMBL913675 | 0.85 | CCNT1 (0.55) | SYKEGFRMAPK8MAPK9MAP4K3 | |
| SCHEMBL913674 | 0.85 | CCNT1 (0.55) | SYKEGFRMAPK8MAPK9MAP4K3 | |
| SCHEMBL913932 | 0.85 | CCNT1 (0.55) | SYKEGFRMAPK8MAPK9MAP4K3 | |
| SCHEMBL912893 | 0.85 | SYK (0.58) | SYKEGFRMAPK8MAPK9MAP4K3 | |
| SCHEMBL912892 | 0.85 | SYK (0.58) | SYKEGFRMAPK8MAPK9MAP4K3 | |
| SCHEMBL913769 | 0.84 | SYK (0.62) | SYKEGFRMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |